The fibrinogen antigenic turbidimetric assay (FIATA): The χ2x̄ test - The corrected chi-square comparison against the control-mean

Clinical and Applied Thrombosis/Hemostasis

Volumn 13, Issue 1, 2007, Pages 73-100

  Stief, Thomas W ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Antigenic; Assay; Chi square; Fibrin; Fibrinogen; Vancomycin

Indexed keywords

ANTITHROMBIN III; ASCORBIC ACID; EDETIC ACID; FIBRIN; FIBRINOGEN; METHIONINE; SINGLET OXYGEN; TISSUE PLASMINOGEN ACTIVATOR; TOSYLCHLORAMIDE SODIUM; VANCOMYCIN;

ACCURACY; ARTICLE; BLOOD VESSEL; BRAIN INFARCTION; BRAIN ISCHEMIA; CHI SQUARE TEST; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOGEN ANTIGENIC TURBIDIMETRIC ASSAY; HEART INFARCTION; HUMAN; HUMAN CELL; NEPHROTOXICITY; PHOTOMETRY; PLASMA; PRECIPITATION; PRIORITY JOURNAL; PURIFICATION; RISK ASSESSMENT; SCREENING TEST; SINGLE DRUG DOSE; STANDARDIZATION; TURBIDIMETRY;

EID: 33845392340     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029606293436     Document Type: Article

References (32)

1. Williams DH. Synthetic chemistry. Sugaring vancomycin. Nature 1999 ; 397: 567-567.
2. Ward TJ, Farris AB III. Chiral separations using the macrocyclic antibiotics: A review. J Chromatogr A 2001 ; 906: 73-73.
3. Stief TW, Kurz J, Doss MO, Fareed J. Singlet oxygen (1O2) inactivates fibrinogen, factor V, factor VIII, factor X, and platelet aggregation of human blood. Thromb Res 2000 ; 97: 473-473.
4. Witko V, Nguyen AT, Descamps-Latscha B. Microtiter plate assay for phagocyte-derived taurine-chloramines. J Clin Lab Anal 1992 ; 6: 47-47.
5. Stief TW, Heimburger N. Inactivation of serine protease inhibitors (serpins) in human plasma by reactive oxidants. Biol Chem Hoppe Seyler 1988 ; 369: 1337-1337.
6. Greenwood PE. A Guide to Chi-squared Testing. New York ; Wiley, 1996.
7. Yates F. Contingency tables involving small numbers and the X2 test. J Roy Stat Soc 1934 ; 1 (Suppl). 217-217.
8. Fisher RA. On a distribution yielding the error functions of several well-known statistics. Proceedings of the International Mathematical Congress, Toronto, 1924: 805-805.
9. Ruggeri ZM. Structure and function of von Willebrand factor: Relationship to von Willebrand's disease. Mayo Clin Proc 1991 ; 66: 847-847.
10. Plaimauer B, Schlokat U, Turecek PL, et al. Recombinant von Willebrand factor: Preclinical development. Semin Thromb Hemost 2001 ; 27: 395-395.
11. Frojmovic MM. Platelet aggregation in flow: Differential roles for adhesive receptors and ligands. Am Heart J 1998 ; 135: S119 - S119.
12. Mosesson M. Dysfibrinogenemia and thrombosis. Semin Thromb Hemost 1999 ; 25: 311-311.
13. Hayes T. Dysfibrinogenemia and thrombosis. Arch Pathol Lab Med 2002 ; 126: 1387-1387.
14. Ashby M, Lazarchick J. Acquired dysfibrinogenemia secondary to mithramycin toxicity. Am J Med Sci 1986 ; 292: 53-53.
15. Aurousseau M, Levacher S, Beneton C. Transient dysfibrinogenemia and thrombocytopenia associated with recurrent acute pancreatitis in the course of isoretinoin therapy. Rev Med Intern 1995 ; 16: 622-622.
16. Henschen-Edman AH. On the identification of beneficial and detrimental molecular forms of fibrinogen. Haemostasis 1999 ; 29: 179-179.
17. Wiman B, Ranby M. Determination of soluble fibrin in plasma by a rapid and quantitative spectrophotometric assay. Thromb Haemostas 1986 ; 55: 189-189.
18. Stief TW. Functional determination of soluble fibrin polymers (SFP) in plasma. Thromb Haemostas 2000 ; 84: 1120-1120.
19. Haddeland U, Bennick A, Brosstad F. Stimulating effect on tissue-type plasminogen activator - a new and sensitive indicator of denatured fibrinogen. Thromb Res 1995 ; 77: 329-329.
20. Inada Y, Hessel B, Blombäck B. Photooxidation of fibrinogen in the presence of methylene blue and its effect on polymerization. Biochim Biophys Acta 1978 ; 532: 161-161.
21. Stief TW, Kretschmer V, Kosche B, et al. Thrombin converts singlet oxygen (1O2)-oxidized fibrinogen into a soluble t-PA stimulator. A new method to prepare a stimulator for functional t-PA assays. Ann Hematol 2001 ; 80: 189-189.
22. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957 ; 17: 237-237.
23. Morse EE, Viswanathan U. Determination of fibrinogen in plasma. Ann Clin Lab Sci 1978 ; 8: 438-438.
24. Furlan N, Felix R, Escher N, Lämmle B. How high is the true fibrinogen content of fibrinogen standards? Thromb Res 1989 ; 56: 583-583.
25. Palareti G, Maccaferri M, Manotti C, et al. Fibrinogen assays: A collaborative study of six different methods. Clin Chem 1991 ; 37: 714-714.
26. Mackie J, Lawrie AS, Kitchen S, et al. A performance evaluation of commercial fibrinogen reference preparations and assays for Clauss and PT-derived fibrinogen. Thromb Haemost 2002 ; 87: 997-997.
27. Launay-Vacher V, Izzedine H, Mercadal L, Deray G. Clinical review: Use of vancomycin in haemodialysis patients. Crit Care 2002 ; 6: 313-313.
28. Wilhelmsen L, Svardsudd K, Korsan-Bengsten K, et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984 ; 311: 501-501.
29. Wright SD, Weitz JI, Huang AJ, et al. Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen. Proc Natl Acad Sci USA 1988 ; 85: 7734-7734.
30. Loike JD, Silverstein R, Wright SD, et al. The role of protected extracellular compartments in interactions between leukocytes, and platelets, and fibrin/fibrinogen matrices. Ann NY Acad Sci 1992 ; 667: 163-163.
31. Rosen H, Klebanoff SJ. Formation of singlet oxygen by the myeloperoxidase-mediated antimicrobial system. J Biol Chem 1977 ; 252: 4803-4803.
32. Stief TW, Fareed J. The antithrombotic factor singlet oxygen/light (1O2/hv). Clin Appl Thromb Hemost 2000 ; 6: 22-22.